Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Tonogenchoncel-L (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Kolon TissueGene
- 05 Apr 2024 Planned End Date changed from 27 Feb 2026 to 6 Mar 2026.
- 22 Jan 2024 Planned End Date changed from 30 Aug 2025 to 27 Feb 2026.
- 22 Jan 2024 Planned primary completion date changed from 30 Aug 2024 to 29 Feb 2024.